APA (7th ed.) Citation

Galactionova, K., Loibl, S., Salari, P., Marmé, F., Martin, M., Untch, M., . . . Schwenkglenks, M. (2022). Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. Frontiers in oncology, 12, 886831. https://doi.org/10.3389/fonc.2022.886831

Chicago Style (17th ed.) Citation

Galactionova, Katya, et al. "Cost-effectiveness of Palbociclib in Early Breast Cancer Patients with a High Risk of Relapse: Results from the PENELOPE-B Trial." Frontiers in Oncology 12 (2022): 886831. https://doi.org/10.3389/fonc.2022.886831.

MLA (9th ed.) Citation

Galactionova, Katya, et al. "Cost-effectiveness of Palbociclib in Early Breast Cancer Patients with a High Risk of Relapse: Results from the PENELOPE-B Trial." Frontiers in Oncology, vol. 12, 2022, p. 886831, https://doi.org/10.3389/fonc.2022.886831.